- Home
- CBZ vs CELC Comparison
CBZ vs CELC Comparison
Compare CBZ & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | CELC |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CBZ | CELC |
|---|---|---|
| Price | $50.77 | $99.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $100.13 |
| AVG Volume (30 Days) | 520.9K | ★ 858.2K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,675,607,000.00 | N/A |
| Revenue This Year | $55.67 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $30.43 | ★ N/A |
| Revenue Growth | ★ 59.19 | N/A |
| 52 Week Low | $47.89 | $7.58 |
| 52 Week High | $90.13 | $112.64 |
Technical Indicators
Market Signals| Indicator | CBZ | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 53.75 |
| Support Level | $50.83 | $98.48 |
| Resistance Level | $53.57 | $103.09 |
| Average True Range (ATR) | 1.38 | 3.83 |
| MACD | -0.20 | -1.22 |
| Stochastic Oscillator | 10.29 | 15.29 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.